Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Abbott Ventricular Tachycardia PAS
NCT05839873 · View on ClinicalTrials.gov ↗
Study Summary
This post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment. This is a prospective, single arm, open-label, multi-center, observational study.
Conditions Studied
Interventions
- DEVICE FlexAbility SE Ablation Catheter
Study Locations (11)
Florida
- NCH Healthcare System — Naples
Indiana
- St. Vincent Hospital — Indianapolis
Kansas
- Kansas City Cardiac Arrhythmia Research Foundation — Overland Park
Massachusetts
- Massachusetts General Hospital — Boston
Minnesota
- VA Medical Center Minneapolis — Minneapolis
North Carolina
- Carolinas Medical Center — Charlotte
Oklahoma
- Integris Baptist Medical Center — Oklahoma City
South Carolina
- Medical University of South Carolina — Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2026-11 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05839873
The ClinicalTrials.gov registry entry for NCT05839873 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention — of which FlexAbility SE Ablation Catheter is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05839873 reports 11 study locations spanning 11 distinct geographic areas — top geographies include Florida, Indiana, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05839873 about?
NCT05839873 is a clinical study titled "Abbott Ventricular Tachycardia PAS". This post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment. This is a prospecti...
What is the current status of trial NCT05839873?
This trial is currently active not recruiting. The enrollment target is 62 participants. The study started on 2023-07-24. Estimated completion is 2026-11.
What conditions does trial NCT05839873 study?
This clinical trial studies the following conditions: Ventricular Tachycardia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05839873?
The interventions under investigation include: FlexAbility SE Ablation Catheter (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05839873?
This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05839873 being conducted?
This trial has 11 study locations across Florida, Indiana, Kansas, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.